loader image

Global Regenerative Trade



CureOs® synthetic bone graft is used to help repair all bone defects which occur in iatrogenic or acquired way. CureOs strongly supports new bone formation and helps the cure of bone defects with surgical intervention.  


why us





about the product



Silicate – Substituted Technology

​CureOs contains >95% Tri-Calcium Phosphate/Silicate
and Silicone.

High Level of Porosity

CureOs has 1 – 550 µm diameter pores, 1% – 80%
overall pore volume


Rapid Resorption Rate

CureOs is expected to expose to biodegradation partially or completely 6-12 months after it is implanted.

Designed in different dimensions

Cube, granule, strip, wedge block and putty in order to adapt different bone defect dimension and geometry.

CureOs® CUBE




CureOs® HTO



CureOs -TriCalcium Phosphate/Silicate Bone Grafts are synthetic, osteoconductive, 80% porous, interconnected macroporosity and microporosity structured, resorbable and biologically compatible bone graft substitute materials.

Osseointegration, Osteogenesis, Osteoconductive, Osteoinductive.

The graft materials used have one or more of osseointegration, osteogenesis, osteoconductive or osteoinductive properties.

Osteoporosis disease

Artificial bone tissue is used to strengthen the bone formation in osteoporosis disease.

Different dimensions

Artificial bone tissue shaped according to the place where it will be used can vary from dust and particles to structural blocks that represent the long bone or spine.

Total porosity

Therefore, the product is designed to allow renewal of bone and blood circulation as pore diameter and total porosity.





  • General bone defects repairment

  • Metaphysial defects repairment

  • Reconstruction, augmentation and filling maxillofacial region

  • Arthrodesis and benign tumor treatment


  • Spinal defects repairment

  • Sinus rifts

  • Filling of endodontic defects

  • Ridge augmentation

  • Cavity filling in bone tissues

CureOs is designed in different dimensions such as cube, granule, strip, wedge block and putty in order to adapt different bone defect dimension and geometry.

The balance between formation and resorption is called homeostasis. It can be assumed that formation and resorption has completely renewed in about 4 to 10 years depending on the size of the bone. Unlike other tissues and organs, bone tissue repair is like a form of self-renewal, which is called regeneration. The regeneration and repair does not occur without blood circulation. Therefore, the product is designed to allow renewal of bone and blood circulation as pore diameter and total porosity.

The growth plate that provides the longitudinal growth of the bone is physiology. While epiphysis provides support to the articular cartilage, metaphysis is present in the metaphysis where the spongiform bone is found intensely. Moreover, functional resistance, carrier and compressive strength come front in the diaphysis where the most thick and dense of the cortical bone is. Artificial bone producers bring together both cortical and spongiform bone (cancellous), as well as approaches that combine two of them recently. Artificial bone tissue shaped according to the place where it will be used can vary from dust and particles to structural blocks that represent the long bone or spine. Besides the material properties of the bone tissue, its hierarchical structure also affects its mechanical properties.

KSP value


 The solubility ratios of bioceramics are expressed by the KSP value. Sintered HA solubility is the lowest bioseramic and the KPS value is between 10-50 and 10-60. KPS value of bone is 10-32. The KPS value of calcium phosphate cements is the same as bone. The KPS value of betatricalcium phosphate is about 10-20 and the KPS value of calcium sulphate is about 10-8. The reason for these substances to dissolve at different times when applied to the human body is the KPS values. In addition, as their porosity increases and their density decreases, the dissolution rates of bioceramics increase naturally. Due to its chemical structure, surface area, pore size and porosity, almost all artificial bone tissue ceramics of mineral origin, when applied to tissue, initiate an inflammatory process similar to that of early fracture healing. The first cells that interact with artificial bone tissue are monocytes and are assumed to cause the release of interleukin (IL) -1 beta (B), IL-6 and tumor necrosan agent alpha (TNF-a). The endothelial cells and neutrophils cause factors making vessel, and prostaglandin 2 starting solubility. Immediately after bone destruction, fibroblast growth factor (FGF) 2 starting bone repair, platelet derived growth factor (PDGF) and transforming growth factor (TGF) beta is released and then process is started. In this way, the artificial bone tissue collapses from one side and the other is replaced by the new bone tissue. The relationship between bone and artificial bone tissue may differ in the presence of radiotherapy, systemic diseases such as diabetes affecting the circulation, drugs used as anti-inflammatory or steroid, and infection. Decomposition of the artificial tissue and giving its place to the new bone tissue take place from the outside to inside and from the periphery to center. In order to increase the mechanical properties of artificial bone tissue that exemplifies the intercellular network, silicon is added to the composition of glass.

Bone tissue is the deposition of many minerals and trace elements other than calcium and phosphate.


. In recent years, these elements have been tried to be included in the composition of bio-systems. There are some studies about adding sodium and magnesium to the structure of bioceramics. Bone grafts and bone substitutes are increasingly used to treat bone defects during reconstructive procedures such as trauma, bone infections, congenital anomalies, musculoskeletal tumor surgery, revision arthroplasty surgery, and spinal surgery. The clinical success in use is determined by the structural integration of the formed bone with the surrounding bone tissue as a result of the reconstructed bone and the mechanical strength of the formed bone to function.



Vivostat Logo


The uniqueness of the Vivostat® system is a novel patented biotechnological process that enables reliable and reproducible preparation of autologous Fibrin Sealant or Platelet Rich Fibrin (PRF®) without using cryoprecipitation and without the need for a separate thrombin component.


  • The Processor Unit is a non-sterile, reusable, fully automated device that controls the biochemical process.
  • The Processor Unit is used to process the patient’s blood and prepare the Vivostat® Fibrin Sealant or Vivostat PRF® solution.
Vivostat Processor Product
  • The Processor Unit is operated by a single button and a display keeps the nurse informed of the remaining process time and status at all times. No specific installation is required and the large wheelbase makes moving it easy.
  • The Processor Unit can be located in any room or corridor in the operating department. It is most often placed centrally between the operating theatres. This way one Processor Unit can supply a number of operating theatres.
  • In approx.  25 min a concentrated fibrin sealant or PRF® solution is prepared from the patient’s whole blood.
  • The Applicator Unit is a non-sterile, reusable, fully automated device that controls the delivery of the Vivostat® Fibrin Sealant or Vivostat PRF®.
Vivostat Processor Product
  • The large display and integrated microprocessor automatically primes the Spraypen® and informs the surgeon of the remaining volume of fibrin sealant/PRF® throughout the entire process.
  • Different spray modes can be selected depending on the actual procedure or area to be covered. Like the Processor Unit it has a large wheelbase and can easily be moved if required.
  • The disposable set comprises of two parts: A Preparation Kit used to prepare the fibrin sealant or PRF® solution before surgery, and an Application Kit used to activate and apply the fibrin sealant/PRF® solution.


  • Preparation Kit
    The Preparation Kit contains the specially designed Preparation Unit – a sterile disposable device in which the patient’s blood is collected, the biochemical process carried out, and the fibrin sealant or PRF® solution harvested.


  • The Application Kit
    The Application Kit contains the Spraypen®1 and all other items required to prepare the system for the delivery of the fibrin sealant or PRF® solution. The Spraypen® is a sterile, disposable, hand held device which delivers the fibrin sealant or PRF® solution to the tissue. The revolutionary and patented design offers the surgeon unparalleled freedom in controlling the application unlike any other product on the market today.


1Besides the Spraypen®, the Vivostat® system offers different types of applicators, e.g. the Endoscopic Applicator. For a full list of application devices click here

1-2-3 Spray

Three easy steps to prepare Vivostat® Fibrin Sealant or Vivostat PRF®

1. Draw blood from the Patient

Fibrin Prep With Blood Inside

At the time of surgery or up to 24 hours before1, citrate (supplied with the kit) is added to the Preparation Unit. 120 ml of the patient’s own blood is then drawn into the same unit.

2. Process the patient’s blood

Vivostat Processor 800

The Preparation Unit is placed in the Processor Unit. At the touch of a button the process starts; after approx. 25 minutes, an autologous fibrin or PRF® solution is ready for use. No thrombin or bovine components are added to the blood at any time.

3. Load the Applicator Unit and spray

Vivostat Display Applicator

The Fibrin or PRF® solution is easily loaded into the Applicator Unit and applied to the surgical site using one of the unique application devices (e.g. the Spraypen). 1This depends on the type of kit being used. Always consult the “Instructions for Use” supplied with the kit to determine the correct preparation.

The following video illustrates how to prepare and apply autologous fibrin sealant.

Presentation DVD from Vivostat A/S on Vimeo.